New JAMA Medical Journal Article Reports A Significant Higher Hypophosphatemia Incidence Rate With Injectafer Compared To Monoferric
In this earlier article, "Injectafer-Induced Hypophosphatemia Can Be A Serious Side Effect Of This Iron Deficiency Anemia Drug", we considered how Injectafer (ferric carboxymaltose) can cause hypophosphatemia as a side effect.
Two main points from that earlier article about Injectafer are:
- According to medical studies, the Injectafer active ingredient ferric carboxymaltose can cause hypophosphatemia (HPP); and,
- Injectafer is the only iron deficiency anemia treatment intravenous product approved by the FDA which is formulated with ferric carboxymaltose.
A February 4, 2020 Original Investigation piece published by the JAMA medical journal article, "Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia -- Two Randomized Clinical Trials", reports on new medical research examining the incidence rate of hypophosphatemia (HPP) with Injectafer compared to Monoferric (ferric derisomaltose), another intravenous iron deficiency anemia drug.
These excerpts from the Abstract for this February 2020 JAMA report sets the stage for a finding of more medical evidence about the increased risk of hypophosphatemia associated with Injectafer:
Importance: Intravenous iron enables rapid correction of iron-deficiency anemia, but certain formulations induce fibroblast growth factor 23–mediated hypophosphatemia.
Objective: To compare risks of hypophosphatemia and effects on biomarkers of mineral and bone homeostasis of intravenous iron isomaltoside (now known as [Monoferric (ferric derisomaltose)] vs [Injectafer (ferric carboxymaltose)].
Strictly Confidential, No Obligation.
From a Key Points prelude found with the online version of this February 2020 JAMA report we get this important Injectafer drug safety information:
Findings: In 2 randomized trials of 245 total patients (trial A: n = 123; trial B: n = 122) with iron-deficiency anemia, who were intolerant to or unresponsive to oral iron, the incidence of hypophosphatemia with use of [Monoferric (ferric derisomaltose)], compared with [Injectafer (ferric carboxymaltose)], was 7.9% vs 75.0% in trial A and 8.1% vs 73.7% in trial B over 35 days; both differences were statistically significant.
These Injectafer safety findings can be put otherwise to make the importance more apparent:
- The hypophosphatemia incidence rate with Injectafer was 75% compared to 7.9% for Monoferric in the first trial; and,
- The hypophosphatemia incidence rate with Injectafer was 73.7% compared to 8.1 % for Monoferric in the second trial.
As mentioned in our earlier article about Injectafer, Severe Hypophosphatemia (Severe HPP) can go on to cause the following medical complications:
We are investigating possible drug injury lawsuits for patients who are diagnosed with hypophosphatemia following their Injectafer treatment and thereafter develop a related medical complication.
DrugInjuryLaw.com: Medical & Legal Information About Drug Side Effects (All website content by attorney Tom Lamb)
Drug Injury Case Evaluation - Free. Confidential. No Obligation. (Case review is done by attorney Tom Lamb)